These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 15515031)

  • 1. Dopaminagonists and fibrotic valvular heart disease: further considerations.
    Rascol O; Pathak A; Bagheri H; Montastruc JL
    Mov Disord; 2004 Dec; 19(12):1524-5. PubMed ID: 15515031
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pergolide use and heart valve fibrosis. Yearly control in patients with Parkinson disease who use pergolide].
    van Laar T; Berendse H; Bloem BR; Boon AJ; van Hilten JJ; Hovestadt A; de Koning-Tijssen MA; Nijssen PC; Weber WE
    Ned Tijdschr Geneeskd; 2009 Jan; 153(3):87-90. PubMed ID: 19235345
    [No Abstract]   [Full Text] [Related]  

  • 3. Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared.
    Chaudhuri KR; Dhawan V; Basu S; Jackson G; Odin P
    Mov Disord; 2004 Dec; 19(12):1522-3. PubMed ID: 15515009
    [No Abstract]   [Full Text] [Related]  

  • 4. Dopamine agonists and valvular heart disease.
    Linkova H; Ruzicka E; Penicka M
    N Engl J Med; 2007 Apr; 356(16):1676; author reply 1678-80. PubMed ID: 17447279
    [No Abstract]   [Full Text] [Related]  

  • 5. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
    Antonini A; Poewe W
    Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additional insights into pergolide-associated valvular heart disease.
    Lanier WL
    Mayo Clin Proc; 2003 Jun; 78(6):684-6. PubMed ID: 12934776
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined pergolide-associated valvular heart disease and achilles tendon contractures.
    Freeman WD; Dorsher PT; Safford RE; Van Gerpen J; Edwards WD
    Acta Med Acad; 2012; 41(2):228-30. PubMed ID: 23331401
    [No Abstract]   [Full Text] [Related]  

  • 8. Pergolide in Parkinson's disease: time for a change?
    Grosset KA; Grosset DG
    Lancet; 2004 Jun; 363(9424):1907-8. PubMed ID: 15183636
    [No Abstract]   [Full Text] [Related]  

  • 9. Pergolide and valvular heart disease: the lower the better?
    Droogmans S; Cosyns B; Van Camp G
    Eur J Echocardiogr; 2008 Nov; 9(6):717-8. PubMed ID: 18641388
    [No Abstract]   [Full Text] [Related]  

  • 10. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.
    Kim JY; Chung EJ; Park SW; Lee WY
    Mov Disord; 2006 Aug; 21(8):1261-4. PubMed ID: 16685692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Organ changes induced by ergot derivative dopamine agonist drugs: time to change treatment guidelines in Parkinson's disease?].
    Roth J; Ulmanová O; Růzicka E
    Cas Lek Cesk; 2005; 144(2):123-6. PubMed ID: 15807300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New concerns about old drugs: Valvular heart disease on ergot derivative dopamine agonists as an exemplary situation of pharmacovigilance.
    Rascol O; Pathak A; Bagheri H; Montastruc JL
    Mov Disord; 2004 Jun; 19(6):611-3. PubMed ID: 15197697
    [No Abstract]   [Full Text] [Related]  

  • 13. Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do.
    Sherlock M; Toogood AA; Steeds R
    Heart; 2009 Apr; 95(7):522-3. PubMed ID: 19174419
    [No Abstract]   [Full Text] [Related]  

  • 14. Pergolide-associated valvular heart disease.
    Waller EA; Kaplan J
    Compr Ther; 2006; 32(2):94-101. PubMed ID: 16845152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.
    Van Camp G; Flamez A; Cosyns B; Weytjens C; Muyldermans L; Van Zandijcke M; De Sutter J; Santens P; Decoodt P; Moerman C; Schoors D
    Lancet; 2004 Apr; 363(9416):1179-83. PubMed ID: 15081648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cardiac valvulopathy and dopamine agonist].
    Grandas F
    Neurologia; 2007 Dec; 22(10):870-81. PubMed ID: 17671852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.
    Andersohn F; Garbe E
    Mov Disord; 2009 Jan; 24(1):129-33. PubMed ID: 19170199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Valvular heart disease associated with the treatment of Parkinson disease].
    Rasmussen VG; Dupont E; Østergaard K; Egeblad H
    Ugeskr Laeger; 2006 Jun; 168(26-32):2542-4. PubMed ID: 16824407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High risk factors for valvular heart disease from dopamine agonists in patients with Parkinson's disease.
    Oeda T; Masaki M; Yamamoto K; Mizuta E; Kitagawa N; Isono T; Taniguchi S; Doi K; Yaku H; Yutani C; Kawamura T; Kuno S; Sawada H
    J Neural Transm (Vienna); 2009 Feb; 116(2):171-8. PubMed ID: 19082526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.
    Senol MG; Togrol RE
    Neurology; 2007 Jul; 69(1):117; author reply 117-8. PubMed ID: 17606893
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.